EchoGo Amyloidosis vs EchoNext
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Both tools leverage AI for cardiac disease detection and are FDA-cleared, making them broadly comparable in their aim to improve cardiac diagnostics. However, EchoGo Amyloidosis specifically targets early detection of cardiac amyloidosis using echocardiogram video clips, while EchoNext offers a broader screening for various structural heart diseases, including heart failure and valve disease, utilizing standard ECGs. Therefore, the choice between them depends on the specific diagnostic focus required.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Amyloidosis is designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7, returning findings directly into existing clinical systems. EchoNext integrates with the OpenEvidence clinical decision support platform, which is used by many physicians, aiming to embed screening outputs directly into common clinical workflows without requiring a separate system.
EchoGo Amyloidosis has demonstrated high diagnostic accuracy with 85% sensitivity and 93% specificity for detecting cardiac amyloidosis. EchoNext, in a retrospective analysis, achieved an area under the receiver operating characteristic (AUROC) of 85.2% for detecting composite structural heart disease and outperformed cardiologists in accuracy (77% vs. 64%).
EchoGo Amyloidosis is specifically designed as a screening tool for cardiac amyloidosis, indicated for adults aged 65 years and older with heart failure undergoing echocardiographic assessment. EchoNext is a broader screening tool for hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, utilizing standard ECGs.
EchoGo Amyloidosis is fully automated and analyzes echocardiogram video clips, requiring no additional workflow steps for clinicians to review results alongside routine studies. EchoNext analyzes standard 12-lead ECGs, and while it provides an algorithmic risk score, its standalone accuracy surpassed cardiologists, suggesting it can augment existing interpretation without a steep learning curve for basic use.
Ultromics offers dedicated support and customer success teams to provide guidance and insights for optimizing workflow with EchoGo Amyloidosis. Pathway Labs, the company behind EchoNext, has raised funding to support expansion across health systems and further clinical validation, implying resources for implementation.
EchoGo Amyloidosis aims to improve early detection of cardiac amyloidosis, a life-threatening condition where timely diagnosis is critical for effective new therapies, by identifying subtle patterns often missed by the human eye. EchoNext is designed to detect hidden structural heart disease from routine ECGs, potentially catching dangerous conditions earlier and streamlining patient care by flagging high-risk patients for timely echocardiography.
While specific audit-trail features are not detailed for either tool, EchoGo Amyloidosis is designed for secure healthcare deployment with ISO 27001 and Cyber Essentials certifications, and US HIPAA risk assessments, suggesting a robust security posture that would likely include tracking and logging capabilities for data integrity. EchoNext's silent deployment studies, where scores were stored but did not influence care, indicate a capability to track and analyze the AI's output against actual patient outcomes.